ScoreComparison
Why is Cyclacel Pharmaceuticals, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate 2.04% of over the last 5 years
2
With a growth in Operating Profit of 138.55%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -1.09 MM
- NET PROFIT(Q) At USD -0.41 MM has Grown at 88.55%
- RAW MATERIAL COST(Y) Fallen by -2,351% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -79.22%, its profits have risen by 48.4%
4
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 1.14% over the previous quarter and collectively hold 3.81% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 15.36% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -79.22% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Cyclacel Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Cyclacel Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Cyclacel Pharmaceuticals, Inc.
-79.22%
-0.40
124.96%
S&P 500
15.36%
1.17
13.09%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.55%
EBIT Growth (5y)
2.04%
EBIT to Interest (avg)
-18.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.13
Sales to Capital Employed (avg)
0.04
Tax Ratio
31.89%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.67%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.69
EV to EBIT
-0.12
EV to EBITDA
-0.12
EV to Capital Employed
0.33
EV to Sales
1.06
PEG Ratio
NA
Dividend Yield
38.70%
ROCE (Latest)
-281.49%
ROE (Latest)
-97.67%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -1.09 MM
NET PROFIT(Q)
At USD -0.41 MM has Grown at 88.55%
RAW MATERIAL COST(Y)
Fallen by -2,351% (YoY
NET SALES(9M)
Higher at USD 1.78 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 3.09 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.47 times
PRE-TAX PROFIT(Q)
At USD -0.4 MM has Grown at 48.52%
-3What is not working for the Company
NET PROFIT(9M)
At USD -10.75 MM has Grown at -25.4%
CASH AND EQV(HY)
Lowest at USD 7.13 MM
Here's what is working for Cyclacel Pharmaceuticals, Inc.
Net Sales
At USD 1.78 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -1.09 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
At USD -0.41 MM has Grown at 88.55%
over average net sales of the previous four periods of USD -3.54 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Pre-Tax Profit
At USD -0.4 MM has Grown at 48.52%
over average net sales of the previous four periods of USD -0.77 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Inventory Turnover Ratio
Highest at 3.09 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.47 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 1.78 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -2,351% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Cyclacel Pharmaceuticals, Inc.
Cash and Eqv
Lowest at USD 7.13 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
